Efficacy and Safety of MOLEQURE - Respiratory Health Supplement on Lung Function

An Open-Label, Single-Arm, Pilot Study to Evaluate the Efficacy and Safety of MOLEQURE - Respiratory Health Supplement on Lung Function in Moderate-to-Heavy Smokers and Individuals with Stable Mild-to-Moderate Respiratory Disease (Asthma/COPD) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108464

Enrollment

Registered

2026-04-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: MOLEQURE - Respiratory Health Supplement: 500 mg capsule of Justicia adhatoda extract and bromelain

1 capsule twice daily for 60 days Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: Male or female participants; Laboratory parameters including CBC, LFT, RFT within clinically acceptable ranges; Moderate to Heavy Smokers with post-bronchodilator FEV1 greater than 60% predicted and FEV1 and FVC ratio greater than 0.65; Resting SpO2 greater than 92 percent; Mild to moderate asthma or GOLD Stage 1 to 2 COPD; Subject with stable inhaled therapy; Chest X ray without significant abnormality

Exclusion criteria

Exclusion criteria: Severe or unstable asthma or COPD; Acute respiratory infection; Use of systemic corticosteroids or immunosuppressants; Current use of chronic oxygen therapy or NIV; Known chronic pulmonary disorders other than asthma or COPD; Significant cardiovascular, hepatic, renal, or other systemic disease; Pregnant or breastfeeding women; Participation in another clinical trial; Known allergy to product ingredients

Design outcomes

Primary

Measure	Time frame
Change in Lung Function score and Pulmonary Function parameters including FEV1, FVC, FEV1 and FVC ratioTimepoint: Lung Function Score will be assessed at Baseline, Day 30 and Day 60. Pulmonary Function parameters will be evaluated at Screening and Day 60	—

Secondary

Measure	Time frame
Changes in arterial blood gas parameters including PaO2, PaCO2, and SaO2, C-reactive protein and IgE levels, chest X-ray findings, use of rescue medications, CBC, blood Glucose, LFT, Renal function, incidence and severity of adverse eventsTimepoint: Baseline to Day 60	—

Countries

India

Contacts

Public ContactMr Manik Chaudhuri

BIORADIAN LIFESCIENCE

amal.bioradian@gmail.com8697612674

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026